Advertisement

Insulin Pharmacodynamics, Pharmacokinetics, and Insulin Regimens

  • Sanjeev Kelkar
  • Shubhangi Muley
  • Prakash Ambardekar
Chapter

Abstract

Pharmacodynamics is the action the drug has on the body. The main elements connected with it are the plasma concentration, protein binding, and the receptor affinity. Half-life in plasma is the duration in which the drug level falls to 50%. Pharmacokinetics is how the drug travels in the body over time and their variations in concentration across time in blood. So far we have dealt with considerable details both these aspects of insulin in the body tissues and cells. Here these functions will be more fully understood against the backdrop of pharmacotherapy of insulin and its pharmacokinetics from a different perspective in all kinds of situations in diabetes.

References

  1. 1.
    Insulin pharmacology Lutz Heinemann, 2002.Google Scholar
  2. 2.
    Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780–8.CrossRefGoogle Scholar
  3. 3.
    Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363–8.CrossRefGoogle Scholar
  4. 4.
    Meyer C, Boron A, Plummer E, Voltchenok M, Vedda R. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study. Diabetes Care. 2010;33:2496–501; http://care.diabetesjournals.org on 30 Aug 2010.CrossRefGoogle Scholar
  5. 5.
    Chawla M, Malve H, Shah H, Shinde S, Bhoraskar A. Safety of intravenous insulin Aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience. J Diabetes Metab Disord. 2015;14:20.CrossRefGoogle Scholar
  6. 6.
    Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.CrossRefGoogle Scholar
  7. 7.
    Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52(4):649–62, Published online: 14 Jan 2015.CrossRefGoogle Scholar
  8. 8.
    Home P, Bartley P, Russell-Jones D, et al. Study to evaluate the administration of detemir insulin efficacy, safety and suitability (STEADINESS) study group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081–7.CrossRefGoogle Scholar
  9. 9.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26:724–36.CrossRefGoogle Scholar
  10. 10.
    Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005;22:850–7.CrossRefGoogle Scholar
  11. 11.
    Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590–6.CrossRefGoogle Scholar
  12. 12.
    De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005;7:73–82.CrossRefGoogle Scholar
  13. 13.
    Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther. 2004;6:579–88.CrossRefGoogle Scholar
  14. 14.
    Bott S, Tusek C, Jacobsen LV, et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabet Med. 2006;23:522–8.CrossRefGoogle Scholar
  15. 15.
    Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med. 2006;23:729–35.CrossRefGoogle Scholar
  16. 16.
    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622–9.CrossRefGoogle Scholar
  17. 17.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med. 2008;25:916–23.CrossRefGoogle Scholar
  18. 18.
    Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.CrossRefGoogle Scholar
  19. 19.
    Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–81.CrossRefGoogle Scholar
  20. 20.
    Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48:1988–95.CrossRefGoogle Scholar
  21. 21.
    Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–20.CrossRefGoogle Scholar
  22. 22.
    Becker RH, Frick AD, Teichert L, et al. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects. Diabetes Obes Metab. 2008;10:1105–13.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Sanjeev Kelkar
    • 1
  • Shubhangi Muley
    • 2
  • Prakash Ambardekar
    • 3
  1. 1.Private PracticePuneIndia
  2. 2.Senior Consultant AnesthesiologistCentral India Institute of Medical ScienceNagpurIndia
  3. 3.Consultant, AnesthesioligistFortis S L Raheja HospitalMumbaiIndia

Personalised recommendations